# Replacing BPA: Structural Substitutes BPAF Binding to the Progesterone Receptor Elevates Breast Cancer Risk

**Authors:** Xiaotong Ji, Peilin Li, Haoyang Wu, Linzhuo Shen, Xiaoyun Wu, Peiyun Jiang, Yating Li, Xiaozheng Zhang, Huifeng Yue

PMC · DOI: 10.1002/advs.202502444 · Advanced Science · 2025-11-07

## TL;DR

This study shows that BPA substitutes like BPAF may increase breast cancer risk by binding to the progesterone receptor, suggesting these replacements are not safer.

## Contribution

The study reveals that BPA analogs, including BPAF, bind to the progesterone receptor and promote breast cancer progression, challenging the assumption that BPA substitutes are safer.

## Key findings

- BPAF and BPB bind more strongly to the progesterone receptor than BPA.
- BPAF exposure increases PR expression and tumor growth in mice.
- BPAF's effects are suppressed by a progesterone receptor inhibitor.

## Abstract

As the global production of bisphenol analogs (BPs) surges to replace regulated bisphenol A (BPA), their pervasive environmental presence and uncharacterized breast cancer risk raise critical public health concerns. Herein, the environmental risks of BPs are deciphered by linking their structural affinity for the progesterone receptor (PR), a master regulator of breast cancer, to oncogenic outcomes across experimental tiers. Molecular simulations reveal that environmental BPAF and BPB exhibited stronger binding to the PR‐ligand binding domain (LBD) than BPA. Chemical assays confirm persistent PR‐LBD structural changes after BPs exposure, mimicking endocrine disruption patterns. The cellular thermal shift assay also confirms the interaction between the PR and BPs. In vitro, BPAF and BPF boost PR expression at human‐relevant concentrations. In addition, BPAF elevates PR expression, and the enhanced migratory and invasive capacities are effectively suppressed by the PR inhibitor. Toxicological Prioritization Index‐based risk stratification, weighted by the binding affinity of BPs to the PR and cellular toxicity, ranks BPAF as the highest‐risk analog. Alarmingly, low‐dose BPAF exposure (30 µg kg−1) accelerates mammary tumor growth in mice, paralleling PR upregulation in tumor tissues. This study underscores that substituting BPA with structurally akin analogs merely shifts, rather than mitigates, environmental health risks.

This study demonstrates that bisphenol analogues, particularly BPAF, bind to progesterone receptor, promoting breast cancer cell proliferation, migration, and mammary tumor growth, indicating that bisphenol A substitutes may pose equal or greater health risks.

## Linked entities

- **Proteins:** PGR (progesterone receptor)
- **Chemicals:** bisphenol A (PubChem CID 6623), BPA (PubChem CID 6623), BPAF (PubChem CID 73864), BPF (PubChem CID 12111)
- **Diseases:** breast cancer (MONDO:0004989)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}
- **Diseases:** toxicity (MESH:D064420), Breast Cancer (MESH:D001943), endocrine disruption (MESH:D004700), tumor (MESH:D009369), mammary tumor (MESH:D015674)
- **Chemicals:** BPA (MESH:C006780), bisphenol (MESH:C543008), BPAF (MESH:C089739), BPB (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12822391/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12822391/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC12822391/full.md

---
Source: https://tomesphere.com/paper/PMC12822391